
    
      This study consists of two parts. In Part 1, ASP1941 or placebo will be administered orally
      in a blind manner. In Part 2, the long-term safety and efficacy of ASP1941 will be evaluated
      in patients who have participated in the study and completed the Part 1.
    
  